Who
Neil Gallagher
Director
Company insider
Files Form 4 as: Director, Foghorn Therapeutics; President, Head of R&D, Syndax Pharmaceuticals; Director, Zymeworks.
In numbers
- Trades disclosed
- 13
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $72K
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 10 Apr 2023
- Last trade
- 24 Jun 2026
- Last filed
- 25 Jun 2026
Companies traded
Activity over time
1 Feb 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 25 Jun 2026 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $114K28,000 at $4.08 | filing |
| 24 Jun 2026filed 25 Jun 2026 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $114K28,000 at $4.08 | filing |
| 1 May 2025filed 2 May 2025 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $208K50,000 at $4.16 | filing |
| 10 Feb 2025filed 12 Feb 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $72K4,618 at $15.50 | filing |
| 5 Feb 2025filed 7 Feb 2025 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $1.6M110,500 at $14.65 | filing |
| 5 Feb 2025filed 7 Feb 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 5 Feb 2025filed 7 Feb 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —23,400 at $0.00 | filing |
| 10 Dec 2024filed 12 Dec 2024 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 2 Apr 2024filed 2 Apr 2024 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,000 at $0.00 | filing |
| 7 Feb 2024filed 9 Feb 2024 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $1.5M69,375 at $22.28 | filing |
| 7 Feb 2024filed 9 Feb 2024 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —34,688 at $0.00 | filing |
| 7 Feb 2024filed 9 Feb 2024 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —13,125 at $0.00 | filing |
| 10 Apr 2023filed 12 Apr 2023 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $4.8M250,000 at $19.35 | filing |
News
Syndax Pharmaceuticals, Inc. (SNDX) Investigation: Bronstein, Gewirtz ...SNDX · pr-inside.com · 22 Oct 2026Syndax Pharmaceuticals (SNDX) – Analysts' Recent Ratings ChangesSNDX · dailypolitical.com · 19 Oct 2026Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down – Here's WhySNDX · tickerreport.com · 15 Oct 2026
0 headlines in the last 90 days name Neil Gallagher; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.